RAPID ALERT

DRAP ALERT No: I/S/01-25-01

CRACKDOWN AGAINST FALSIFIED PRODUCTS

Date: 02nd January, 2025.

Target Audience:

- National Regulatory Field Force of DRAP and Provincial Drug Control Departments
- Healthcare Professionals (Physicians, Pharmacists & Nurses)
- General Public

Alert Summary:

Directorate of Drugs Control (DDC) Punjab has informed DRAP that samples various products have been identified as spurious (falsified). Details of test reports are as under:

S#	Product Name	Batch No.	Manufacturer stated on label	Test Results
01	Injection Penbiotic (Procaine Penicillin 1500000IU, Benzyl Penicillin 500000IU, Streptomycin Sulphate 5g) Reg# 0221448	V044B23	Purported to be manufactured by Nawan Laboratories, Karachi	Substandard & Spurious
02	Orthoplast Plaster of Paris bandage 10cm x 2.7cm Reg# MDME-0000149	03E24	Purported to be manufactured by Cotton Craft (Pvt.) Ltd., Lahore	Spurious
03	Suspension Carfen 90ml (Ibuprofen 100mg/5ml) Reg# 066500	CN-035	Purported to be manufactured by Well care Pharmaceuticals Sargodha	Spurious & Misbranded
04	Novidat tablet 500,g (Ciprofloxacin 500mg) Reg# 011837	FIM063	Purported to be manufactured by Sami Pharmaceuticals Karachi	Spurious

Action initiated:

The field force under administrative control of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.

Advice for Pharmacies/Medical stores and Healthcare Professionals:

All pharmacists and chemist working at distributions and pharmacies should **immediately check** their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and

DRAP, Islamabad + 92 051 9255969 gsms@dra.gov.pk

returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) should also increase surveillance in the market to ensure the effective recall of defective products(s). DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by batches of mentioned products. Adverse reactions or quality problems experienced with the use of these products are to be reported to the National Pharmacovigilance Centre (NPC), DRAP using Adverse Event Reporting Form or online through this link. Further information of reporting problems to DRAP is available on this link.

Advice for Consumers / general public:

Consumers should stop using products bearing the affected batch number(s) and shall contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product, and report the incident to Drug Regulatory Authority of Pakistan/ National Pharmacovigilance Centre.

Drug Regulatory Authority of Pakistan
محفوظ، موئثر اور معیاری اشیائے علاج

DRAP, Islamabad
+ 92 051 9255969
gsms@dra.gov.pk